Related Experiment Video
Updated: Jul 8, 2025
Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
An Overview of Meningococcal Disease's Recent Diagnostic and Treatment Model
Deepali Chhabria1, Ashish Anjankar2
1Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Abstract:
In healthy people, Neisseria meningitidis (the meningococcus) is a typical component of the nasopharyngeal microbiome, but in those who are susceptible, it can cause septicemia and meningitis. This section gives a general overview of the meningococcus types and the sickness induced by N. meningitidis. Evaluate genes for phase-changeable adhesions, virulence factors, and effective colonization of the human host. In our final section, we summarize the evolution of meningococcal vaccines and their current state while emphasizing the value of ongoing molecular research into the pathogen's epidemiology and structural analysis of its antigens. IMD is a major global source of morbidity and mortality and a public health concern. IMD can manifest as an epidemic with breakouts or as an endemic illness with sporadic instances. There are 13 serogroups of Neisseria meningitis strains, however, only five (A, B, C, W-135, and Y) account for the majority of IMD globally. IMD poses a risk to people of all ages, although young children and teenagers are especially at risk. Meningitis and septicemia are the two clinical symptoms of IMD that occur most frequently, while both clinical presentations can occasionally exist. Age might affect the clinical pattern; in early childhood, the clinical manifestations could be more subtle, and the diagnosis may be trickier than in older kids or teenagers. In 4.3-11.2% of instances, there are sequelae, and death occurs in 6-10% of cases. Although vaccination remains the most effective method of preventing meningococcal disease, it is crucial to identify children with meningococcal infection as soon as possible to begin systemic antibiotic therapy. The prevalence of the disease has decreased as a result of the recent introduction of various meningococcal vaccinations on a global scale. Increasing meningococcal disease vaccination rates, keeping an eye on IMD, and creating a special vaccine that can protect against all of the major meningococcal strains should be the priorities for the upcoming few years.
Insights
Neisseria meningitidis causes meningitis and septicemia globally. Meningococcal vaccines have reduced disease prevalence, but ongoing research is vital for developing broader protection against this public health threat.
Area of Science:
- Microbiology
- Epidemiology
- Vaccinology
Background:
- Neisseria meningitidis (meningococcus) is a common nasopharyngeal bacterium that can cause severe invasive meningococcal disease (IMD) in susceptible individuals.
- IMD is a significant global health concern, leading to meningitis and septicemia, with particular risk to young children and adolescents.
- While 13 serogroups exist, five (A, B, C, W-135, Y) are responsible for most global IMD cases.
Purpose of the Study:
- To provide an overview of meningococcus types and the diseases they cause.
- To review virulence factors and host colonization mechanisms of N. meningitidis.
- To summarize the evolution, current status, and future directions of meningococcal vaccines, emphasizing molecular research.
Main Methods:
- Literature review and synthesis of existing data on meningococcal epidemiology, pathogenesis, and vaccinology.
- Analysis of gene functions related to bacterial adhesion, virulence, and colonization.
- Evaluation of historical and current vaccine strategies and their impact.
Main Results:
- Invasive meningococcal disease (IMD) is a major cause of morbidity and mortality, with significant sequelae and mortality rates (6-10%).
- Recent introduction of meningococcal vaccines has led to a global decrease in disease prevalence.
- Vaccination is the primary prevention strategy, alongside prompt antibiotic treatment for infected individuals.
Conclusions:
- Continued molecular research into N. meningitidis epidemiology and antigen structure is crucial for advancing vaccine development.
- Priorities include increasing vaccination rates, surveillance of IMD, and developing a universal vaccine against major meningococcal strains.
- Effective prevention relies on vaccination, early diagnosis, and antibiotic therapy.
